Page last updated: 2024-12-07
centa
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CENTA: structure; beta-lactamase chromogenic cephalosporin reagent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 133358 |
CHEMBL ID | 1650032 |
SCHEMBL ID | 10876201 |
MeSH ID | M0105145 |
Synonyms (11)
Synonym |
---|
80072-86-2 |
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((3-carboxy-4-nitrophenyl)thio)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, (6r-trans)- |
centa |
(6r,7r)-3-[(3-carboxy-4-nitrophenyl)sulfanylmethyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
CHEMBL1650032 |
DTXSID40230061 |
SCHEMBL10876201 |
9073-60-3 |
(6r,7r)-3-[(3-carboxy-4-nitrophenyl)sulfanylmethyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid |
centa(tm) beta-lactamase substrate |
AKOS040751071 |
Research Excerpts
Overview
CENTA is a newly synthesized, beta-lactamase-labile, chromogenic cephalosporin reagent.
Excerpt | Reference | Relevance |
---|---|---|
"CENTA is a newly synthesized, beta-lactamase-labile, chromogenic cephalosporin reagent which changes color from light yellow (lambda maximum ca. " | ( In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent. Barry, AL; Jones, RN; Novick, WJ; Thornsberry, C; Wilson, HW, 1982) | 2.02 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Other Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Beta-lactamase | Klebsiella pneumoniae | Km | 24.0000 | 1.0000 | 4.4500 | 7.9000 | AID1320835 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (16)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1320835 | Activity of native signal containing Klebsiella pneumoniae OXA-48 by Michaelis-Menten kinetics assay | 2016 | Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11 | Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening. |
AID562326 | Activity of Aeromonas hydrophila metallo-betalactamase CphA N233A mutant expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. |
AID766241 | Activity at recombinant VIM-2 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID562324 | Activity of Aeromonas hydrophila metallo-betalactamase CphA expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. |
AID766244 | Activity at recombinant Bc2 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID766246 | Ratio of Kcat to Km for recombinant VIM-2 (unknown origin) | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID766247 | Ratio of Kcat to Km for recombinant IMP-1 (unknown origin) | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID766249 | Ratio of Kcat to Km for recombinant Bc2 (unknown origin) | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID766243 | Activity at recombinant SPM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID766248 | Ratio of Kcat to Km for recombinant SPM-1 (unknown origin) | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID766242 | Activity at recombinant IMP-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID562327 | Ratio of Kcat to Km for Aeromonas hydrophila metallo-betalactamase CphA N233A mutant expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. |
AID766240 | Activity at recombinant NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID562325 | Ratio of Kcat to Km for Aeromonas hydrophila metallo-betalactamase CphA expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. |
AID766245 | Ratio of Kcat to Km for recombinant NDM-1 (unknown origin) | 2013 | Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17 | Assay platform for clinically relevant metallo-β-lactamases. |
AID1320836 | Activity of native signal containing Klebsiella pneumoniae OXA-48 assessed as ratio of Kcat to Km by Michaelis-Menten kinetics assay | 2016 | Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11 | Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 75.62
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (75.62) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |